Guselkumab Plus Golimumab Promising Combination For Ulcerative Colitis Patients who received combination therapy with guselkumab and golimumab followed by maintenance treatment with guselkumab achieved clinical remission a (mmayo b) at week 38 (47.9 percent [34 71]) versus 31.0 percent (22 71) and 20.8 percent (15 72) of patients who received guselkumab or golimumab alone, respectively (nominal p=<0.05). 1. At week 38, 34 (48%) of 71 patients in the combination therapy group, 15 (21%) of 72 patients in the golimumab monotherapy group, and 22 (31%) of 71 patients in the guselkumab group had clinical remission according to the modified mayo score and 49 (69%) patients in the combination therapy group, 43 (60%) patients in the golimumab monotherapy.
Guselkumab Golimumab Combination Provides Superior Clinical Remission Golimumab group, and 75% of patients in the guselkumab group achieved clinical response. when the therapeutic target of clinical remission, a more stringent and regulatory accepted endpoint was evaluated, a larger treatment effect was observed at week 12 between combination therapy and guselkumab monotherapy than for clinical response at week 12. Both a lower and higher dose of guselkumab were used and the results showed that clinical remission occurred in 25.7% and 25.2% of patients receiving the lower and higher dose respectively. in the vega trial presented at ueg, researchers examined the safety and efficacy of combination therapy with guselkumab and golimumab. all patients were. At week 12, 59 (83%) of 71 patients in the combination therapy group had achieved clinical response compared with 44 (61%) of 72 patients in the golimumab monotherapy group (adjusted treatment difference 22·1% [80% ci 12·9 to 31·3]; nominal p=0·0032) and 53 (75%) of 71 patients in the guselkumab monotherapy group (adjusted treatment. Data from an ongoing analysis of a phase 2a trial showed that adults with moderately to severely active ulcerative colitis (uc) administered 12 weeks of combination induction therapy with guselkumab (janssen pharmaceutical companies of johnson & johnson) and golimumab, followed by a transition to guselkumab alone for maintenance, achieved a clinical remission rate at week 39 of 47.9%.
Guselkumab Golimumab Combo Shows Promise For Ulcerative Colitis At week 12, 59 (83%) of 71 patients in the combination therapy group had achieved clinical response compared with 44 (61%) of 72 patients in the golimumab monotherapy group (adjusted treatment difference 22·1% [80% ci 12·9 to 31·3]; nominal p=0·0032) and 53 (75%) of 71 patients in the guselkumab monotherapy group (adjusted treatment. Data from an ongoing analysis of a phase 2a trial showed that adults with moderately to severely active ulcerative colitis (uc) administered 12 weeks of combination induction therapy with guselkumab (janssen pharmaceutical companies of johnson & johnson) and golimumab, followed by a transition to guselkumab alone for maintenance, achieved a clinical remission rate at week 39 of 47.9%. Charlotte, n.c. — guselkumab in combination with golimumab induced greater rates of clinical remission compared with monotherapy among patients with moderate to severely active ulcerative colitis. At the same time, the rates of clinical remission by modified mayo score also favored the combination group at 48%, followed by 31% in the guselkumab group and 21% in the golimumab cohort.
Comments are closed.